On Wednesday, July 21, 2021, Manuela Albisetti, Head of the Hemophilia Center of the University Children’s Hospital in Zurich, Switzerland, presented results from research that looked at the efficacy and safety of dabigatran in treatment and secondary prevention of venous thromboembolism (VTE) in children with central venous catheter (CVC)- or implantable device (ID)-related thrombosis.